Home » Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement

Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement

Jun 12, 2009

NEW YORK (GenomeWeb News) - Exact Sciences said today that it has signed a deal with the Mayo Clinic for exclusive rights to intellectual property related to stool-based screening for colorectal cancer.

The company said that it has also closed an $8.2 million private placement of 4.3 million shares of its common stock.

Exact gained exclusive rights to technology developed by the Mayo Clinic's David Ahlquist relating to sample processing, analytical testing, and data analysis for non-invasive, stool-based DNA screening for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

An Expensive Deal

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Figuring Out Who It'll Work For

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

Ye Old P-Value

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.